Molecular mechanisms underlying levodopa-induced dyskinesia.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsLevetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the StriatumMultiple roles for nicotine in Parkinson's diseaseAmantadine for dyskinesias in Parkinson's disease: a randomized controlled trialLevodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsCell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice.Convergent evidence for abnormal striatal synaptic plasticity in dystonia.Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysChronic levodopa administration followed by a washout period increased number and induced phenotypic changes in striatal dopaminergic cells in MPTP-monkeysLevodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complicationsControlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.Motor complications, levodopa metabolism and progression of Parkinson's disease.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.Dysregulation of striatal projection neurons in Parkinson's disease.New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.A commentary on: "A 12-year population-based study of freezing of gait in Parkinson's disease".Understanding and prevention of "therapy-" induced dyskinesias.Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q21129423-6C899435-B0CD-4CBF-BDF2-6811C0A534A4Q21284508-31AF9AD5-6F0A-4885-8DB4-A94471BC514EQ22252514-57C75A8C-AB55-4DE0-BC39-6F42EC2AD08CQ27312728-BA6CB753-CAA8-4E18-B0F8-C81C98D31190Q27316872-0D08FB14-6697-401B-8B2C-236FA75E06CCQ33723034-146F78FC-813D-4FDE-8EDE-E12116B7857EQ33756951-FB7653AF-7C89-4425-86B5-D31A527261C2Q33758221-60313639-9DB2-4D6F-B203-595C9AF28386Q34186299-F7CF6C41-EBB3-42FE-895E-BB1CEA3FAF76Q34506001-C3EC963C-3290-4514-827E-4C2088AC54F4Q34708186-A130F753-1D22-47B9-B66B-4D3BD96AB7CAQ35163198-D2AF0C5A-1587-4EA2-BD8B-D5F4D864077EQ35885603-C319F4E7-EE77-44ED-8375-E540C8143761Q35972575-0AD86487-F83C-4C65-8FD2-09629FB29494Q36727014-D1D7BD64-4959-450A-AF64-CCD152B28DD9Q37043711-C4FB631E-2C57-4EA2-B5AE-079570687F75Q37507973-4C0D90C0-4990-421B-AB27-EF9F792722FFQ37863681-F62707FD-F312-4C60-A049-498B082126CEQ37890986-F43D970A-DB06-457A-9E5C-75B2FB16D95DQ37924629-D5D86DFB-2BB6-45B0-9F0C-0D9F2C58F76AQ38103966-BB9025D0-E422-4BBC-9B10-82A06D5F8EC4Q38215506-871EC45E-AB95-4444-9324-51492D1D5F47Q38284574-64CE5EDC-9A98-489D-8E42-21293A5671EAQ38479031-A85ED683-4B5E-462E-A13C-B5ECB90C2273Q38722989-A6AE8716-55E5-4704-A809-E60013B528A1Q39172080-BAF25043-A8A1-4E36-AB57-C83BAC0CB170Q39324877-E3563D8B-EF56-4F6B-85E2-F21CC5FBB69AQ41515796-61D8FB6B-216A-4BDB-A28B-63719602B65AQ42052125-6AC695B1-B0CF-412F-8B8F-7C3E61BFAE3FQ42183668-33164DE9-280A-4332-B1C2-D581FC1266F9Q42859427-A6DA5DFD-5DEA-4D22-B83F-95B84F8D7247Q44050418-B8D33358-9494-4801-BA7F-CE106BAE1AB8Q44925523-187F84BB-07C9-4799-9AC4-6B360723599FQ49926091-E004981B-C63C-4CF6-8FF5-C0ECDB1470F0Q50093660-C4EE95EE-D8F8-4DEE-9468-68CB4C6EA13BQ57518128-E716962A-8372-4C40-B6D4-85030E753C35
P2860
Molecular mechanisms underlying levodopa-induced dyskinesia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular mechanisms underlying levodopa-induced dyskinesia.
@en
Molecular mechanisms underlying levodopa-induced dyskinesia.
@nl
type
label
Molecular mechanisms underlying levodopa-induced dyskinesia.
@en
Molecular mechanisms underlying levodopa-induced dyskinesia.
@nl
prefLabel
Molecular mechanisms underlying levodopa-induced dyskinesia.
@en
Molecular mechanisms underlying levodopa-induced dyskinesia.
@nl
P2860
P356
P1433
P1476
Molecular mechanisms underlying levodopa-induced dyskinesia
@en
P2093
Massimiliano Di Filippo
Paolo Calabresi
P2860
P304
P356
10.1002/MDS.22019
P407
P478
23 Suppl 3
P577
2008-01-01T00:00:00Z